Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
PaxMedica, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 CASAMENTO CHARLES J (Director) has filed a Form 4 on PaxMedica, Inc.
Txns: Paid exercise price by delivering 6,536 shares @ $0.2861, valued at $1.9k
09/27/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/23/2023 4 Rome Zachary (Director) has filed a Form 4 on PaxMedica, Inc.
Txns: Sold 20,000 shares @ $0.5813, valued at $11.6k
Sold 30,000 shares @ $0.5412, valued at $16.2k
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/16/2023 3 Hough David W. (Chief Medical Officer) has filed a Form 3 on PaxMedica, Inc.
08/16/2023 8-K Resignation/termination of a director
Docs: "PaxMedica Appoints David Hough M.D. as Chief Medical Officer"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, August 9, 2023– PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023. Recent Highlights · Announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness Study, PAX-HAT-301, paving the way for an expected NDA filing in 2024 · Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with autism ..."
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 8-K Quarterly results
07/06/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC"
06/16/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PaxMedica Enters Research Collaboration Agreement with PoloMar Health for Phase II Study in Autism Spectrum Disorder"
06/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PaxMedica Completes HAT-301 Registrational Trial for PAX-101 · HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing · Top Line Results Planned for Release in July 2023 Tarrytown, N.Y. June 1, 2023 - PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of Autism Spectrum Disorder , and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company’ s Real World Evidence study has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers. The comparative arms for this ..."
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y. May 15, 2023 - PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023. Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023. The study, if successful, is expected to lead to the submission of a New..."
05/12/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/01/2023 4/A Rome Zachary (COO) has filed a Form 4 on PaxMedica, Inc.
Txns: Paid exercise price by delivering 9,584 shares @ $1.61, valued at $15.4k
05/01/2023 4/A LaRochelle Karen (Director) has filed a Form 4 on PaxMedica, Inc.
Txns: Paid exercise price by delivering 1,143 shares @ $1.61, valued at $1.8k
04/24/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy